MedTrace Logo

Interaction Between Vanoxerine (GBR 12909) and Cocaine in Cocaine Dependent Individuals

NCT00218049 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2017-01-12

No results posted yet for this study

Summary

Cocaine dependence is a major public health problem; an effective primary treatment for cocaine dependent individuals has yet to be found. The purpose of this study is to determine the safety and effects of vanoxerine (GBR 12909) in treating cocaine dependent individuals.

Conditions

  • Cocaine Abuse
  • Cocaine-Related Disorders

Interventions

DRUG

GBR 12909

50mg GBR 12909 over 12 days

DRUG

GBR 12909

GBR 12909 75 mg over 12 day period

DRUG

GBR 12909

GBR 12909 100 mg over 12 day period

Sponsors & Collaborators

  • University of Texas

    collaborator OTHER

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • John Grabowski, PhD · University of Texas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2005-07-31
Completion
2005-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00218049 on ClinicalTrials.gov